Latest news

• Gilead’s latest Biktarvy data offers hope to HIV patients

  Gilead Sciences (Gilead) has announced the latest results from its two phase 3 studies assessing the long-term safety and efficacy profile of Biktarvy for the treatment of people living with ... These outcomes were reported in participants 96 weeks after

• Gilead announces positive Biktarvy data for HIV and hepatitis B

  Biktarvy is a complete HIV treatment, combining three medicines to form the smallest three-drug, single-tablet regimen (STR) available, as a simple once-daily dosing regimen. ... This bolsters the efficacy and tolerability profile of Biktarvy as a

• Gilead sales rise by 13%, buoyed by anti-COVID-19 drug Veklury

  The drop was also partially offset by a 20% increase to $2.3bn from Biktarvy (bictegravir/emtricitabine/tenofovir) and Trodelvy (sacituzumab govitecan-hziy), said Gilead. ... The dynamics of the HIV treatment market further improved and this contributed

• Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit

  Overall, HIV product sales decreased by 12% to $3.7bn for the first quarter, although sales of its newer HIV treatment Biktarvy increased by 8% year-on-year in Q1.

• GSK considers more divestments to help R&D push

  Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) product.